MDMA Assisted Therapy for Bulimia Nervosa

This trial aims to explore whether MDMA-assisted therapy, which combines the drug MDMA with psychotherapy, can effectively treat Bulimia Nervosa, a condition marked by binge eating followed by purging. Researchers aim to determine if MDMA can reduce anxiety and increase openness during therapy. Participants will join one of three groups, each testing different therapy approaches: MDMA with general therapy, MDMA with bulimia-specific therapy, or standard therapy. Suitable candidates have experienced Bulimia Nervosa for some time and found past treatments unsuccessful. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that ongoing therapy with certain psychiatric medications may not be allowed, and medications that prolong the QT/QTc interval cannot be used during experimental sessions. It's best to discuss your specific medications with the study team.

Studies have shown that MDMA-assisted therapy (MDMA-AT) is generally safe and well-tolerated by participants. Research indicates that MDMA-AT can significantly reduce symptoms in people with severe post-traumatic stress disorder (PTSD) without major safety concerns. In trials, most side effects were mild, such as temporary anxiety or a faster heartbeat, and they usually resolved on their own.

Researchers are excited about MDMA-assisted therapy for bulimia nervosa because it introduces a novel approach by combining the psychoactive effects of MDMA with psychotherapy. Unlike existing treatments, such as cognitive-behavioral therapy (CBT) or medications like selective serotonin reuptake inhibitors (SSRIs), MDMA may enhance the therapeutic process by promoting emotional openness and reducing fear and anxiety, which are crucial for addressing deep-seated issues associated with eating disorders. Additionally, this treatment could potentially lead to faster improvements by facilitating more effective therapy sessions, making it a promising avenue for those who haven't responded well to conventional options.

Research has shown that therapy using MDMA, a substance that can increase openness and reduce anxiety, may help treat bulimia nervosa. In this trial, participants will receive either MDMA-assisted therapy with non-specific eating disorder psychotherapy, MDMA-assisted therapy with bulimia nervosa-specific psychotherapy, or standard treatment. Studies suggest that combining MDMA with talk therapy might reduce symptoms of eating disorders. Specifically, for individuals with severe PTSD, MDMA-assisted therapy significantly reduced eating disorder symptoms compared to a placebo. Although more research is needed, these early results offer promising new treatment options for those with bulimia nervosa.²³⁴⁶⁷